Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

Lee M. Krug*, Vincent A. Miller, Jyoti Patel, John Crapanzano, Christopher G. Azzoli, Jorge Gomez, Mark G. Kris, Robert T. Heelan, Barbara Pizzo, Leslie Tyson, Christine Sheehan, Jeffrey S. Ross, Ennapadam Venkatraman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Agricultural and Biological Sciences